IGC Pharma (IGC) Receivables - Net (2011 - 2026)

IGC Pharma (IGC) has reported Receivables - Net for 16 consecutive years, with $37000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Net rose 8.82% year-over-year to $37000.0 in Q1 2026; TTM through Mar 2026 was $37000.0, a 8.82% increase from a year earlier, with the FY2026 full-year figure at $37000.0, up 8.82% from the prior year.
• Receivables - Net was $37000.0 for Q1 2026 at IGC Pharma, up from $12000.0 in the prior quarter.
• Over five years, Receivables - Net peaked at $251000.0 in Q4 2022 and troughed at $12000.0 in Q4 2025.
• A 5-year average of $96705.9 and a median of $87000.0 in 2025 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net plunged 87.56% in 2024 and soared 210.71% in 2025, its largest moves.
• Over 5 years, Receivables - Net stood at $251000.0 in 2022, then tumbled by 63.35% to $92000.0 in 2023, then plunged by 46.74% to $49000.0 in 2024, then slumped by 75.51% to $12000.0 in 2025, then soared by 208.33% to $37000.0 in 2026.
• The last three Receivables - Net figures came in at $37000.0 (Q1 2026), $12000.0 (Q4 2025), and $41000.0 (Q3 2025), per Business Quant data.